classifi cation system is too simplistic (7) . Indeed, the observation of parkinsonism, dementia, and subclinical peripheral neuropathy in patients with type 1 GD has challenged its more traditional defi nition as non-neuronopathic.
Clinically, GD is highly variable, and genotype-phenotype correlations are limited. Although the spectrum of disease is thought to correlate in part with residual enzyme activity (5), there is substantial clinical heterogeneity, even among siblings and identical twins (8, 9) .
Current treatment for patients with GD include enzyme replacement therapy (ERT) (but this does not cross into the brain and is very expensive) and alternatives such as substrate reduction therapy (SRT) or the use of small molecule enzyme-chaperone therapy (2). Th e last-mentioned has the added benefi t of crossing the blood -brain barrier, providing an opportunity to treat additional features of the disease, e.g. the neurological manifestations of GD. Pharmacological chaperones, e.g. ambroxol and isofagomine, have been shown to bind mutant misfolded GCase stalled in the ER, assisting in the refolding and passage to the lysosome, where the chaperone-enzyme complex dissociates in the low pH and the residual activity of the enzyme can hydrolyse substrate (10,11).
Glucocerebrosidase gene ( GBA )
Th e gene encoding GBA is located on chromosome 1q21 and comprises 11 exons and 10 introns, spanning 7.6 kb of sequence. Located 16 kb downstream and 2 kb shorter is a highly homologous pseudogene ( GPAP ), which has Ͼ 96% identity to the coding regions of the functional gene. Th is complicates sequencing, as many mutations encountered in Gaucher patients are identical to sequences ordinarily found only in the pseudogene. Th us, for diagnostic purposes it is essential to diff erentiate between sequences from the gene and the pseudogene. So far 300 pathogenic mutations throughout the GBA gene have been identifi ed (12), including point mutations, insertions, deletions, frameshift mutations, splice-site alterations, and recombinant alleles that encompass segments of the pseudogene sequence. Th e c.1226A Ͼ G (N370S) mutation is the commonest GBA mutation in the literature followed by c.1448T Ͼ C (L444P) (2). Th e frequency of the GBA mutations, however, varies according to the diff erent ethnicity. For instance, in the Ashkenazi Jewish population, 1 in 14 -18 carries a GBA mutation. Th erefore, screening for GBA mutations common in Ashkenazi Jews could be cost-eff ective but is not a reliable strategy for other ethnic groups, in which GBA mutations are found in less than 1% and a large number of diff erent mutations are seen. Moreover, the N370S variant, although frequent among those of European, American, or Middle Eastern origin, is not typically seen in Chinese or Japanese populations (13, 14) .
The link between GBA mutations and Parkinson disease
Among the neurological complications of type 1 GD is parkinsonism. Th is has challenged the traditional classifi cation of type 1 GD as non-neuropathic. Th e possibility of a link between the two diseases was fi rst suggested in the clinic setting where a small number of case reports described parkinsonian features in GD patients (15 -17) . Larger studies have since been published which have confi rmed these fi ndings (18, 19) . Heterozygote carriers of mutations in the GBA gene also have an increased frequency of Parkinson disease (PD) (20, 21) , and approximately 5% -10% of PD patients have GBA mutations (22 ,23 ) , confi rming mutations of this gene as numerically the most important genetic predisposing risk factor for PD identifi ed to date.
Studies describing the penetrance and lifetime relative risk (RR) of PD in patients with GD and heterozygote GBA mutation carriers are summarized in Table I . Data are confl icting, with some studies reporting a slightly higher estimated penetrance and lifetime RR of PD in heterozygous GBA mutation carriers compared to GD patients. Th is may refl ect diff erences in the size of the cohorts that were evaluated, rather than a signifi cant diff erence in the overall risk of PD between the two groups.
Studies have investigated the frequency of GBA mutations in patients with sporadic PD and have shown that the odds ratio for a known patient with idiopathic PD to harbour one GBA mutation is 5.4 (22) . In other words, patients with PD are fi ve times more likely to carry GBA mutations than healthy controls. Moreover, when compared to other PD-related genes, such as α -synuclein (SNCA) and parkin, the frequency of GBA mutations is higher in individuals with parkinsonism (24). Of further interest is a recent study that has identifi ed a GBA mutation, E326K, that can predispose to PD but is a variant that does not, when homozygous, cause GD (25).
GBA mutations in other synucleinopathies
GBA mutations have been identifi ed in other Lewy body disorders including dementia with Lewy bodies (DLB), Lewy body variant Alzheimer disease (LBV-AD), but not multiple-system atrophy (MSA). Th ese disorders, known as synucleinopathies, are characterized by the deposition of fi brillated SNCA within brainstem or cortical inclusion bodies.
In an autopsy study of 75 cases with pathologically confi rmed Lewy body (LB) disorders, GBA mutations were identifi ed in 23% of cases with DLB, 4% of those with PD, and none with MSA (32). Furthermore, in a recent report, those with DLB were eight times more likely to carry a mutation in GBA than healthy controls, suggesting GBA mutations may play an even greater role in the genetic aetiology of DLB than in PD (33). Conversely, studies in MSA patients, including 108 British pathologically confi rmed cases (34), have not identifi ed signifi cant diff erences in the GBA mutations observed in cases and controls. Th is suggests a distinct pathogenesis for MSA, a disease in which SNCA is deposited in oligodendroglial cytoplasmic inclusions rather than neurons, that is not just related to PD but also shares traits of a demyelinating disorder. Th is also emphasizes the relationship between GBA mutations and SNCA neuronal aggregation in PD and DLB. Moreover, GBA mutations have not been identifi ed in patients with progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) (35).
GBA -associated PD
GBA -related parkinsonism largely resembles sporadic PD, but it has been characterized by some subtle diff erences, for instance a younger age of onset (36), a higher frequency of cognitive decline (36,37), bradykinesia (38), olfactory dysfunction (37), and a lower frequency of rigidity (39).
Clinical phenotype

Parkinsonism in GD patients
PD is typically characterized by the motor symptoms of resting tremor, bradykinesia, rigidity, and postural instability. Patients with GD who develop parkinsonism typically exhibit the symptoms of sporadic PD. Th e majority of patients with type 1 GD who developed PD therefore present with asymmetric onset, tremor, and bradykinesia (37), the cardinal features of ' idiopathic ' PD. In an early case series of six type 1 GD patients (40), parkinsonism developed at a mean age of 49 years and manifested atypical fi ndings such as psychiatric symptoms, myoclonus, and an unresponsiveness to L-dopa therapy. Other atypical features have also been observed such as perceptive deafness (19), dementia (18), and horizontal saccadic eye movements (18).
Parkinsonism in GBA heterozygotes
Table II summarizes all the published studies looking at the frequency and clinical features of PD patients with mutations in GBA . In patients with PD who had heterozygous mutations in GBA , Neumann et al. (36) reported hallucinations in 45% and signs of cognitive decline or dementia in 48% by the time the patient died. A study of Spanish PD patients with heterozygous GBA mutations confi rmed an increased frequency of dementia (41). Furthermore, in a recent longitudinal ( ∼ 71 months) community-based unselected PD cohort, there was a signifi cantly greater risk for progression to dementia in heterozygote GBA mutation carriers (42).
Response to treatment
Reports on the effi cacy of L-dopa treatment in patients with PD and mutations in GBA have been confl icting. Most studies report a good or excellent response to L-dopa treatment in heterozygote GBA mutation carriers (36,43), as would be expected in the presynaptic dopamine defi ciency seen in PD with and without GBA mutations, but some report a less favourable response (18).
Cognitive impairment and neuropathological fi ndings
Th e pathological hallmarks of PD include a loss of dopaminergic neurons from the substantia nigra (SN) and the deposition of LBs in the remaining nerve cells of aff ected brain regions. Neuropathological fi ndings demonstrate that GBA-PD brains show the typical hallmarks of sporadic PD, such as brainstem and cortical LBs (36, 44) . GCase is an important component of SNCApositive pathological inclusions (45) . Immunohistochemistry of seven brain samples from subjects carrying GBA mutations (three individuals with GD and four with heterozygous mutations in GBA ) and with pathological diagnoses of PD and/or DLB demonstrated a co-localization of mutant GCase and SNCA in protein aggregates and LBs. In contrast, in samples from those without GBA mutations, Ͻ 10% of LBs were GCase-positive (45) .
Th ere are several reports now demonstrating more cognitive impairment in GBA-PD (22, 46, 47) . It is interesting to speculate that the cognitive impairment in GBA-related parkinsonism results from a higher burden of LB disease than sporadic PD. Two autopsy studies demonstrated that, in addition to the classic PD pathology, in PD patients with heterozygous GBA mutations SNCA inclusions were detectable in cortical areas corresponding to Braak stages 5 to 6, suggesting GBA mutation carriers may have more extensive neuropathological disease (36,48). However, in a later study on the same autopsies, authors did not identify increased LB pathology in PD associated with GBA mutations (49). Th e fi ndings from both cellular and animal studies suggest that mutant GBA can promote the accumulation of SNCA (50) and led authors to propose that any subsequent formation of SNCA oligomers could kill the cell prior to LB formation (49).
Non-motor symptoms
By the time the classic motor problems of PD develop, it is estimated that over 50% of dopaminergic neurons in the SN pars compacta have degenerated (76). Th ere is now evidence that the PD neurodegeneration process begins long before the onset of the motor involvement (77,78). During this period, other neurotransmitter systems may also degenerate and are associated with non-motor symptoms (NMS), including olfactory and autonomic dysfunction, sleep disorders, mood changes, and cognitive decline. Th e recognition that the pathological process may start outside of the SN (79) explains why some of these NMS manifest before motor problems emerge, and can therefore precede the diagnosis of PD. Moreover, NMS occur more frequently in GBA-PD (31). Th erefore, further screening for non-motor manifestations is needed in GBA mutation-positive individuals prior to conversion to PD, to develop an early biomarker set to predict individual pre-symptomatic risk of conversion to clinical PD.
Neuroimaging
Dopamine imaging by single photon emission tomography (SPECT) of the dopamine transporter and positron emission tomography (PET) are abnormal in patients with PD and GBA mutations, in a pattern that is similar to sporadic PD (80). In a PET study to investigate underlying dopaminergic dysfunction in GBA mutation carriers with and without parkinsonism, Kono et al. demonstrated presynaptic dopaminergic dysfunction characteristic of sporadic PD in both a patient with GD and PD, and three subjects with heterozygous GBA mutations and PD (81). In another study, homozygous and compound heterozygous GBA mutation carriers identifi ed through screening of 250 Ashkenazi Jewish parkinsonian individuals were assessed with 18F-fl uorodopa PET and showed bilateral reductions in striatal F-dopa uptake, similar to idiopathic PD (64). However, fi ndings from a larger study showed that although the pattern of dopamine loss is similar in patients with GD and PD to that seen in patients with sporadic PD, H 2 15O PET demonstrates reduced resting regional cerebral blood fl ow in additional areas (precuneus and lateral parietal-occipital association cortex bilaterally) in patients with PD and GBA mutations, in a pattern characteristic of diff use LB disease (82).
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For personal use only. In idiopathic PD, transcranial sonography (TCS) detects SN hyperechogenicity in 90% of patients, which likely refl ects increases in local iron content and microglial activation. However, there are concerns regarding the specifi city and sensitivity of this technique in PD. SN echogenicity is a fi nding that may also change over time in a normal individual (83). Furthermore, there is no relationship of the TCS abnormalities to PD stage or progression. Nevertheless, nigral hyperechogenicity has also been a reported feature of PD associated with GBA mutations, and there is a comparable degree of SN hyperechogenicity and common features regarding SN pathology (84). Recent evidence suggests, however, that this is a frequent fi nding in GD patients, irrespective of whether they had developed PD or not, and could be related to disturbances of iron metabolism in GD (85).
Cerebrospinal fl uid fi ndings
In patients with PD and GBA mutations there are altered cerebrospinal fl uid (CSF) fatty acid levels compared with patients with idiopathic PD (86). In a study comparing CSF fatty acid concentrations in 41 patients with idiopathic PD and 8 patients with PD associated with heterozygous GBA mutations, results demonstrated specifi c abnormalities of fatty acid metabolism in those with GBA mutations, which authors propose may be involved in the pathogenesis of PD (86). Larger studies would be needed to confi rm this. Of further interest is a 12-year follow-up study of a case of PD in a patient who later developed GD (87). Th e cognitive decline and cortical atrophy seen in this patient were not paralleled by any change of dementia markers in the CSF. Concentrations of tau and amyloid-β (proteins elevated in Alzheimer disease) remained normal, while concentrations of monoamine metabolites were low. Th is could suggest the cognitive decline observed in this patient with GBA mutations involved pathogenetic pathways other than those typically found in Alzheimer disease.
Proposed mechanisms linking GBA and PD pathogenesis
Th e mechanisms by which GBA mutations result in PD are not yet understood (Figure 1) . Most autosomal recessive forms of PD, such as PINK1, DJ-1, and parkin, are associated with loss-offunction mutations and early-onset disease. In contrast, autosomal dominant forms are attributed to a gain-of-function mutation. GD is an autosomal recessive disorder. However, the inheritance of PD caused by GBA mutations does not follow a strict Mendelian pattern. Th erefore, in GBA-PD, both gain-of-function and enzymatic loss-of-function models have been put forward (88) to explain how mutations in GBA contribute to the pathogenesis of PD. Mutations in GBA could result in a mutant misfolded protein. Misfolded GCase could lead to the development of PD by promoting SNCA accumulation or preventing its degradation. Alternatively, the misfolded protein could cause lysosomal dysfunction by overwhelming the ubiquitin-proteasome pathway (UPS) or by impairment of autophagy. Most mutations in GBA are missense mutations that give rise to a misfolded protein, and therefore this favours a gain-of-function model. However, some studies have implicated GBA mutations that do not encode the glucocerebrosidase protein, e.g. 84GG null allele, in patients who also go on to develop PD (59). Albeit rare, these mutations could argue against an exclusively gain-of-function mechanism.
Alternatively, parkinsonism could arise from a defi ciency/ reduction of wild-type (WT) GCase resulting from a loss-offunction mutation, with subsequent substrate accumulation and altered lipid homeostasis, or lysosomal dysfunction. Neither Experimental evidence now suggests that GCase interacts directly with SNCA at membranes, within lysosomes (97). Th e interaction site has been mapped to the C-terminus of SNCA. It has also been suggested that the binding between the WT enzyme and SNCA, under lysosomal conditions, could have a benefi cial eff ect by either promoting SNCA degradation by the lysosome and/or preventing aggregation (98). Th e authors propose another self-perpetuating model. Mutations in GCase or reduced levels of WT GCase reaching the lysosome could weaken the benefi cial interaction between SNCA and GCase, reduce lysosomal protein degradation, and contribute to the SNCA aggregation characteristic of PD pathology. Th e resultant accumulation of substrate and SNCA would then mediate the interaction of the SNCA-GCase complex on intralysosomal vesicles, leading to a further loss of GCase activity (97).
Recent studies therefore demonstrate a reciprocal relationship between GCase and SNCA (89,94), which not only contribute to our understanding of the pathogenesis of GBA-PD and idiopathic PD but also highlight an important therapeutic target. Modulating GCase activity or improved targeting of WT GCase to lysosomes could be an important therapeutic approach for PD (88,99).
Th is gain-of-function model, however, does not explain why only a minority of GD patients or carriers of GBA mutations ever develop PD. Other pathological factors may be at work and help determine whether a positive feedback loop can surpass the cellular homeostatic mechanisms to an extent that the levels of SNCA become toxic. It could be that GBA contributes to SNCA pathology, but only in the presence of other insults, e.g. increasing age, where the number of lysosomes and lysosome function decreases and cellular SNCA concentrations increase. Another possibility is that GBA may act as a ' second hit ' in some individuals who are genetically predisposed to develop PD (88). model, however, explains why only a minority of patients with mutations in GBA go on to develop PD.
A synucleinopathy
Th e synucleinopathies are all characterized by the presence of aggregated insoluble SNCA, in the form of amyloid fi brils, within LBs of the central nervous system. Th e presence of mutant GCase in SNCA-positive LBs, as demonstrated by immunohistochemistry studies (45) , has suggested a relationship could exist between the two proteins. GCase defi ciency, overexpression of mutant GBA , or inhibition of GCase by condruitol β -epoxide (CBE) can interfere with the clearance of or promote the aggregation of SNCA (89 -95). Furthermore, augmenting GCase activity can reduce SNCA levels (50). Albeit, a recent report did not fi nd any signifi cant alteration in SNCA levels following GCase inhibition with CBE (96), but this probably refl ected too short a period of toxin exposure (92).
Increased SNCA results in a decrease in GCase protein and activity in cells. SNCA can also aff ect the transport of GCase from the ER/Golgi apparatus to the lysosome (89,94). Recent evidence has suggested a self-propagating feedback loop in GD and synucleinopathies. A defi ciency of GCase may lead to an accumulation of substrate, which could in turn infl uence the amyloid formation of SNCA, and the resulting toxic build-up of insoluble SNCA within lysosomes could compromise lysosomal protein degradation. SNCA could then impair the traffi cking of GCase, exacerbating substrate accumulation and SNCA aggregation (89). Th e further fi nding that GCase is reduced in the SN in PD brains with or without GBA mutations (94) suggests that SNCA could cause GCase defi ciency directly, even in the absence of mutant enzyme, and this could be exacerbated in GBA-PD and hold signifi cance for the wider PD population. Mutations in GBA can cause GCase to fold abnormally, whereupon it is arrested in the ER, targeted by endoplasmic reticulumassociated degradation (ERAD), and translocated to the cytoplasm for degradation by the UPS. Th is results in decreased amounts of GCase protein present in the lysosome, and the degree of ER retention and proteasomal degradation is thought to correlate with the severity of GD (115).
Th e unfolded protein response (UPR) is activated in response to ER stress, aids the elimination of misfolded proteins, and is neuroprotective (116). Misfolded GCase arrested in the ER can cause ER stress, activate the UPR, and aff ect the UPS degradation of other proteins, e.g. SNCA, thereby allowing them to accumulate. Markers of the UPR are increased in both GBA-PD and sporadic PD brains and may play a role in reducing protein levels (94).
However, only one study has shown a direct relationship between PD and GBA which involves ERAD (117). Parkin and mutations in its encoding gene (PARK2) cause early-onset PD. Parkin is an E3 ubiquitin lipase, ubiquitinating proteins for destruction by the lysosome or the proteasome. A loss of normal parkin leads to impaired degradation of some of its substrates, including SNCA, and to their accumulation. Parkin also forms part of the UPR, enhancing removal of misfolded proteins from the ER (118). One theory proposed is that mutant GBA could interact with parkin to block its interaction with other substrates, impairing their degradation via the UPS and exacerbating ER stress, leading to neuronal death with the development of PD (117). Th is theory has attracted some criticism. Th e role of parkin is not restricted to the UPS and the targeting of proteins for degradation, and evidence from a recent report in fi broblasts suggests parkin is not a critical ubiquitin ligase for GCase (119).
Dysfunctional mitophagy
Th e turnover of mitochondria by mitophagy, a form of autophagy, is essential for the protection of neurons. If damaged mitochondria are not removed, reactive oxygen species and free radicals are allowed to accumulate, causing damage to neurons and eventual cell death. Th erefore, mitochondrial dysfunction and oxidative stress are thought to be important in PD pathogenesis (120). Several studies have shown that PD causative genes are implicated in mitochondrial morphology and function (121). For instance, PINK1 and parkin play a pivotal role in mitochondrial quality control (122). Parkin binds to the mitochondrial membrane in response to a fall in membrane potential (123), and the selective recruitment of parkin to damaged mitochondria is mediated by PINK1 through direct phosphorylation (124).
Despite this, the evidence in the literature for a role of mitochondrial dysfunction or mitophagy in PD patients with GBA mutations remains limited. Of recent interest was a study suggesting that inhibition of GBA activity could induce the abnormalities in mitochondrial function and oxidative stress previously only seen in sporadic or familial PD. Authors showed that inhibition of GBA in cell culture leads to decreased ADP phosphorylation, reduced mitochondrial membrane potential and increased free radical damage, together with accumulation of SNCA (92). Th is implies that mutations in GBA could increase the risk of PD through abnormalities in mitochondrial function. However, the mechanism for this remains uncertain. Of further relevance is a recent mouse model of GD where there was an accumulation of dysfunctional mitochondria as a result of impaired autophagy and proteasomal pathways. Both lysosomes and mitochondria have a role in autophagy and organelle turnover, and authors suggest that the pathogenesis
Autophagic dysfunction
In PD, the accumulation of SNCA and other ubiquitinated proteins within LB inclusions has implicated protein mishandling in the pathogenesis of the disease. Abnormal protein accumulation appears in both PD and GD and may infl uence the severity of disease. Proteins are degraded via the lysosome or the proteasome. Th e lysosome is the major cellular compartment for protein degradation (100), and within the lysosome the degradation of proteins occurs through three distinct pathways: macroautophagy, microautophagy, and chaperonemediated autophagy (CMA). Th e lysosomal autophagy process destroys misfolded, long-lived or aggregate-prone proteins in the cell and, in doing so, confers a cytoprotective role (101) . Defective autophagy and/or depletion of lysosomes have been implicated in PD pathogenesis (102 -105) and in a Gaucher mouse model (90). In addition, disruption of the lysosomal autophagy process has been suggested as the mechanism by which mutations in LRRK2, a gene responsible for autosomal dominant PD, could exert its eff ects (106,107).
Evidence for the role of the lysosome under conditions of protein burden came from a study looking at the overexpression of SNCA in transgenic mice (108). Overexpression led to its subsequent enhanced clearance by the lysosomal CMA pathway. Th is was demonstrated by an up-regulation of lysosome-associated membrane protein type 2A (LAMP-2A) and lysosomal heat shock cognate protein of 70 kDa (hsc70), two mediators of CMA. An important point to note, however, is the compensatory action of macroautophagy on specifi cally blocking CMA (104). Rapamycin, an inducer of macroautophagy, reverses the SNCA accumulation caused by the overexpression of D409V glucocerebrosidase (85). Despite this, any up-regulation of macroautophagy may be unable to compensate for all functions of CMA (109).
SNCA is degraded by proteasomal pathways, but to a greater extent through CMA (103). It has been suggested that the efficacy of CMA declines with age (110), with decreasing lysosomal numbers and function. Of particular interest is the evidence of defective CMA in the PD brain. In a post-mortem study of seven PD brains, there was a signifi cant reduction of CMA markers within the SN pars compacta and amygdala compared to controls, and autophagy-related proteins were shown to accumulate in LBs (104). Moreover, gene replacement of beclin 1, which activates autophagy, has been shown to ameliorate the neurodegenerative pathology in animal models of PD and LBD (111).
Th e mechanism by which mutant GCase causes lysosomal dysfunction is not yet understood. Th e decrement in lysosomal function that would result from mutant GBA or decreased amounts of WT GCase reaching the lysosome, could in turn reduce SNCA turnover through CMA and lead to its accumulation and aggregation. Th e suggested benefi cial interaction between SNCA and WT GCase proposed to occur under lysosomal conditions (98) may suggest that techniques to increase GCase activity and improve its delivery to the lysosome could promote degradation through the autophagy pathway and reduce SNCA concentrations.
Endoplasmic reticulum stress and disruption of the ubiquitin-proteasome pathway
Th e ER operates a stringent quality control system to ensure proper protein folding, traffi cking, and degradation. Misfolded proteins are degraded via the UPS. Some studies have demonstrated defects of the UPS in sporadic PD (112, 113) . Despite this, the application of proteasome inhibitors to induce PD in animal models has produced confl icting results (114). aggregates such as SNCA and improved memory defects. It is notable that the memory improvement observed by Sardi and colleagues, in response to glucocerebrosidase administration into the CNS, was seen in both pre-symptomatic (50) and symptomatic mouse models (129), and before any significant protein accumulation had established itself. This has implications for the asymptomatic population at risk of development of PD, e.g. GBA -positive carriers, where modulating GCase activity could be a potential strategy to prevent the onset/ conversion to clinical PD. Moreover, the clinical evaluation of GBA mutation-positive individuals for pre-motor signs of PD could be important not only in developing a clinical biomarker set to predict individual pre-symptomatic risk of conversion to clinical PD, but this cohort would also be invaluable to the assessment of any future therapy to manipulate GCase activity and slow PD progression. Strategies to modulate GCase activity include the use of pharmacological chaperones such as ambroxol or isofagomine, histone deacetylase inhibitors which reduce the recognition of misfolded GCase by the chaperone protein Hsp90 β , and increasing GCase expression, e.g. using gene therapy (99). Enhancing GCase activity in this way and improving lysosomal function could also hold relevance for those with GD, where there is currently no treatment that can cross the blood -brain barrier and treat the neurological forms of the disease.
Why a global genetic defect, such as that which is seen in patients with GBA-PD, shows selective neuronal pathology, including Lewy body formation and loss of dopaminergic neurons, remains unclear. Defects in autophagy and the UPS have been implicated in neurodegenerative disease (130), and it has been proposed that lysosomal storage disorders could be diseases of autophagy (131). Th e level of intracellular SNCA is critical for the onset of neurodegeneration with Lewy bodies and dependent, to a large extent, on degradation via the lysosomal autophagy of neurodegeneration seen in both GD and in PD could result from global defects in proteostasis (95).
Altered lipid metabolism
Defi ciencies in GBA can cause lipids to accumulate. GCase normally degrades glucosylceramide to glucose and ceramide. It has been proposed that changes in ceramide metabolism are associated with LB formation, and ceramide-related genes have been implicated in PD. For instance, a number of genes have been identifi ed which interfere with ceramide metabolism associated with LB pathology (125). It is also thought that focal accumulation of lipids in specifi c brain regions could impair protein degradation through the lysosomal autophagy pathway, and SNCA could accumulate.
SNCA binds to lipids in the plasma membrane and synaptic vesicles (126). Th e helical binding of SNCA to lipid membranes is thought to prevent the formation of its fi brillar forms. Th is property of SNCA to form amyloid fi brils is thought critical for the development of neurotoxicity (89). Th e lipids which accumulate as a result of defi ciencies in GBA could alter the sphingolipid composition of membranes and prevent the membrane binding of SNCA, thereby enhancing its aggregation in the cytoplasm (127).
Despite this, there are limitations to the hypothesis that GBA mutations in patients with PD cause alterations in lipid metabolism due to a loss of functional GCase activity. Ceramide metabolism is thought to be a tightly regulated process, and ceramide can be derived from several diff erent degradative and synthetic pathways. In addition, it is not clear how a partial defi ciency in GCase seen in heterozygotes, insuffi cient to cause substrate accumulation, would impact lipid metabolism signifi cantly. Furthermore, there is no evidence that ceramide is defi cient in those with GD, even those with severe forms of the disease (128).
The future: a role for modulating GCase activity?
GBA has now been identifi ed as numerically the most important genetic risk factor for the development of PD, and, unlike other PD-related genes, considerably more is known about this protein, its processing, and how it functions (88). Although the mechanisms underlying the association between GBA mutations and PD remain unclear, further investigation and understanding of the involvement of this protein as a susceptibility factor for PD and other synucleinopathies is likely to prove valuable. So far to date, the delineation of the diff erent molecular pathways, which underlie the pathogenesis of GBA-PD, has shown there is considerable connection between them.
Recent findings suggest that SNCA and GBA are implicated in a common cellular pathway and are of great significance in understanding the pathogenesis of GBA-PD as well as sporadic PD. SNCA propagation by templating could be promoted by GCase deficiency, e.g. increased SNCA levels, promotion of fibril formation, and increased SNCA endosomal release through lysosomal inhibition. Furthermore, Sardi et al. demonstrate that augmenting glucocerebrosidase activity can modulate SNCA aggregation and could represent a novel therapeutic strategy for PD (99, 129) . In a mouse model of a Gaucher disease (D409V/D409V genotype), there was a progressive accumulation of SNCA, tau, and ubiquitin aggregates in hippocampal neurons and a measurable memory deficit. Increasing glucocerebrosidase activity in this mouse model, through adenoassociated viral vector delivery (AAV) of the recombinant enzyme into the brain, modulated the accumulation of protein pathway. Th erefore, impairment of lysosomal pathways is increasingly viewed as a major pathogenic event and unifying theme in PD (132). Depletion of GCase may result in the toxic accumulation of insoluble SNCA within lysosomes, compromise lysosomal protein degradation, and promote a bidirectional feedback loop in which SNCA accumulates and causes a self-propagating disease (89,94).
Recent developments in this fi eld have put forward an interesting concept. Th e suggested interaction between SNCA and GCase and the ability to manipulate this, using strategies to enhance GCase activity and in turn modulate SNCA aggregation, could provide a novel therapeutic approach for the treatment of PD (Figure 2 ) (99). Th is could be signifi cant for those with GBA-PD, asymptomatic GBA-positive carriers at risk of conversion to clinical PD, or even those with sporadic PD, where reductions in GCase have also been noted and may hold signifi cance (94).
